title: Methotrexate suppresses nitric oxide production ex vivo in macrophages from rats with adjuvant-induced arthritis.
abstract: We examined the effects of methotrexate (MTX) on the level of nitric oxide (NO) produced by peritoneal macrophages from rats with adjuvant-induced arthritis (AA) ex vivo. During the development of AA, paw swelling increased and LPS enhanced the capacity of peritoneal macrophages to produce NO and prostaglandin E2 (PGE2). MTX (0.1 mg/kg, p.o.) treatment for 21 days reduced the paw swelling, and inhibited the increased NO and PGE2 production. However, when MTX (0.1 mg/kg, p.o.) was administered to rats with established AA, these parameters were not significantly influenced. In normal rats, MTX (0.1 mg/kg, p.o.) treatment for 21 days did not change NO and PGE2 production of LPS-stimulated macrophages. On the other hand, macrophages from normal and AA rats cultured in the presence of MTX (1, 10 and 100 microM), were activated by LPS in vitro. MTX did not influence NO or PGE2 production by LPS-stimulated macrophages in normal and AA rats. By contrast, indomethacin (IM) (1.0 mg/kg, p.o.) treatment for 21 days reduced the paw swelling, and inhibited NO and PGE2 production in AA rats. IM inhibited significantly PGE2 production, but did not influence NO production by LPS-stimulated macrophages in vitro. These results suggest that MTX treatment reduces NO production in peritoneal macrophages in AA rats, and these actions of MTX may have an inhibitory effect without the modulation of PGE2.
authors.affiliation: Department of Pharmacology, Zeria Pharmaceutical Co. Ltd, Saitama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Omata
authors.forename: Y
authors.initials: Y
authors.lastname: Segawa
authors.forename: N
authors.initials: N
authors.lastname: Inoue
authors.forename: N
authors.initials: N
authors.lastname: Tsuzuike
authors.forename: Y
authors.initials: Y
authors.lastname: Itokazu
authors.forename: H
authors.initials: H
authors.lastname: Tamaki
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D002469:Cell Separation; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D008070:Lipopolysaccharides; D009569:Nitric Oxide; D007213:Indomethacin; D008727:Methotrexate